on the sarcoplasmic reticulum (SR) membrane of different cell types. RyR type 1 (RyR1)
is the dominant isoform in skeletal muscle and RyR type 2 (RyR2) is abundant in the
heart. The RyR N-terminus is a large cytoplasmic domain that binds many channel
modulators, including the immunophilin calstabin.
Calstabins (FKBPs) which are cis-trans peptidyl-prolyl isomerases modify
and bind to RyRs. Calstabin1 (FKBP12) is associated with RyR1 and calstabin2
(FKBP12.6) binds to RyR2. The binding site for calstabins on RyRs has been studied
and includes a proline. The proline is preceded by a valine or an isoleucine in both RyR
isoforms. Calstabins bind to the immunosuppressive drugs rapamycin and FK506; this
binding suppresses the isomerase activity of these drugs. It has been proposed that this
inhibition is caused by the ability of the immunosuppressive compounds to mimic the
transition state of ligand isomerization.
RyR undergoes several types of post-translational modifications. One of these
modifications, phosphorylation by protein kinase A (PKA) at Ser2808, causes a decrease
in affinity of calstabin to the channel. The dissociation of calstabin from the channel
increases channel openings and promotes sub-conductance states. This phenomenon
causes Ca2+ �leak� from the SR into the cytoplasm and depletes the Ca2+ stores of the cell.
The aberrant release of Ca2+
can promote different disease states. For example, SR Ca
2+
leak in cardiac cells can promote heart failure (HF) and fatal ventricular arrhythmias.
The Marks lab demonstrated that a calstabin2 mutant � in which Asp37 was
mutated into valine � retained the ability to bind to PKA-phosphorylated channels.
Single channel measurements have shown that binding of the calstabin2-D37V restored
the calstabin2-bound channel properties.
In the present study we aimed to structurally understand the differences in binding
between wt-calstabin2 and D37V-calstabin2. To this end, we cloned, expressed and
purified the D37V-calstabin2 with an MBP fusion protein. The fusion protein was
crystallized in the presence of rapamycin and the structure was solved using molecular
replacement techniques. The main difference between the mutant and wt calstabin2 was
that a hydrogen bond between D37 and rapamycin was replaced with a van der Waals
interaction.
We also docked the mutant calstabin2-D37V into our cryo-EM structure of RyR1.
We were able to clearly see that the amino acids D (or V) interacted with a helix
projecting from the RyR structure, which we believe to contain the proline previously
identified by the Marks group. Calstabin2 interacted with the receptor via three distinct
domains; this interaction has implications for coupled gating, phosphorylation and
disease-associated mutations.
The binding affinity of the wt and mutant calstabins was measured using
radiolabeled versions of wt and D37V proteins. We found that the affinity of wt
calstabin2 to PKA-phosphorylated RyR2 decreased threefold compared to non-
phosphorylated RyR. The D37V mutant, however, was able to bind to both
phosphorylated and non-phosphorylated RyR2 with the same affinity.
This study also included efforts to crystallize different RyR fragments. We
attempted to crystallize RyR1 and RyR2 domains that are involved in RyR regulation by
small modulators or domains that are important to its activity. Despite not being able to
crystallize these fragments, we present our results here and suggest they could serve us in
the future for a variety of biochemical and biophysical studies Less
membrane that surrounds the eukaryotic nucleus. Deciphering the molecular structure of the
NPCs is critical to our understanding of both cellular architecture and the mechanism of nucleocytoplasmic transport. In less than a decade, atomic level structures of many nucleoporins
(Nups) have been solved and the molecular picture of the NPC is becoming increasingly clearer.
Nup62�58�54 subcomplex is a nucleoporin subcomplex in the NPC�s central channel, the
molecular structure of which, is not known so far. At a sequence level, the N-terminal half of all
subunits in the complex contain intrinsically disordered phenylalanine-glycine (FG) repeatmotifs. The C-terminal half is structured into coiled-coil domains that engage in tight proteinprotein interactions to hold the complex together and to anchor it to the NPC scaffold. In this
project, I aimed to elucidate the molecular structure of the X.laevis ?FG-Nup62�58�54 complex
by X-ray crystallography. Poor solubility of some coiled-coil domain containing Nups, such as
Nup54, in bacterial expression has been a challenge towards obtaining large amounts of
nucleoporins required for crystallographic analysis. We established a system where all three
subunits of xl?FGNup62�58�54 were co-expressed together in E.coli. The soluble amount of
Nup54 was greatly enhanced, when co-expressed together with its interaction partners.
Biochemical analysis of the recombinant ?FG-Nup62�58�54 complex revealed a monomeric, nonspherical complex with a clear 1:1:1 subunit stoichiometry, which had been unclear so far. Also,
in contrast to previously published reports, the ?FG-Nup62�58�54 complex did not show any
tendency to form protein-concentration dependent higher-order oligomers. However, extensive
crystallization trials failed to crystallize ?FG-Nup62�58�54 complex, probably due to inherent
flexibility in its structure. Therefore, we generated and screened a series of single-domain
antibodies (nanobodies, Nbs) against ?FG-Nup62�58�54 complex and identified a few that
stabilized the trimeric complex but did not recognize any of the individual subunits or dimeric
interactions. Crystallization trials of ?FG-xlNup62�58�54 complex conjugated to one such
nanobody, Nb15, yielded rod-shaped crystals, which are currently limited in their diffraction
potential to ~7.5�. Thus, nanobody conjugation of the ?FG-xlNup62�58�54 complex aided in its
crystallization and can be used as a general approach to stabilize NPC subcomplexes.
Furthermore, a coiled-coil interaction between xlNup93 N-terminus and xlNup62�58�54 complex
is thought to recruit the Nup62�58�54 complex to the NPCs. This interaction in our experiments,
however, turned out to be surprisingly weak. This now predicts additional interaction sites for a
high avidity anchorage of the Nup62�58�54 complex to the NPC scaffold. Less
In this study, I purified different Atg18, Atg21 and Hsv2 PROPPIN homologs and showed that they bind specifically to PI3P and PI(3,5)P2 using protein-liposome co-flotation assays. Recently, we published the first structure of the PROPPIN Hsv2. Based on our structure I performed mutagenesis studies to probe phosphoinositide binding of Hsv2. I analyzed phosphoinositide binding of the alaninine mutants with liposome flotation assays. I identified conserved residues essential for binding right and left of the FRRG motif, indicating the presence of two phosphoinositide binding sites, which was an unexpected finding. Using ITC measurements I then confirmed the binding stoichiometry of two phosphoinositides to one Hsv2 molecule and determined the binding affinities of PROPPINs to both PI3P and PI(3,5)P2 incorporated in small unilamellar vesicles. Phosphoinositide binding of S. cerevisiae Hsv2 is pH dependent. Acidic environment increases and basic environment decreases the affinity. In addition, I showed the involvement of loop 6CD in membrane binding. Mutagenesis analysis of loop 6CD residues revealed that membrane insertion is dependent on both ionic and hydrophobic interactions.
Two ubiquitin-like conjugation systems modifying Atg8 (in mammals MAP1LC3) and Atg12 are essential for autophagy. Homologs of the canonical ubiquitin conjugation system, E1- and E2-like enzymes, are involved in the conjugation of Atg8 and Atg12 to their specific targets phosphatidylethanolamine and Atg5, respectively.
A in vivo reconstitution system for the two human ubiquitin-like conjugation systems Atg12 and MAP1LC3 was established using the MultiBac baculovirus expression system in insect cells. This allowed full length expression of the involved proteins and purification of the Atg5-Atg12 conjugate and lipidated MAP1LC3 in small yields Less
Areas covered: The demand for method developments and also tools for macromolecular crystallography has significantly increased over the past 10 years. As a consequence, access to the facilities required for these investigations, such as synchrotron beamlines, became more difficult and significant efforts were dedicated to the automation of the experimental setup in laboratories. In this article, the authors describe how this was accomplished and how robot-based systems contribute to the enhancement of the macromolecular structure solution pipeline.
Expert opinion: The evolution in robot technology, together with progress in X-ray beam performance and software developments, contributes to a new era in macromolecular X-ray crystallography. Highly integrated experimental environments open new possibilities for crystallography experiments. It is likely that it will also change the way this technique will be used in the future, opening the field to a larger community. Less
picornaviruses which impact on human and animal health. Current picornavirus vaccines are
frequently produced from inactivated virus. Inactivation often reduces the stability of the
virus capsid, causing a problem for Foot and Mouth Disease Virus (FMDV) where certain
serotypes fall apart into pentameric assemblies below pH 6.5 or at temperatures slightly
above 37�C, destroying their effectiveness in eliciting a protective immune response. As a
result, vaccines require a cold chain for storage and animals need to be frequently immunised.
FMDV is a member of the Aphthovirus genus of the Picornaviridae. Globally there are seven
FMDV serotypes: O, A, Asia1, C and SAT-1, -2 and -3, contributing to a dynamic pool of
antigenic variation. As part of collaboration between the Division of Structural Biology,
Oxford University, The Pirbright Institute, Reading University and ARC, Ondespoort, South
Africa we sought to rationally engineer thermo-stable FMDV capsids either as infectious
copy virus or recombinant empty capsids with improved thermo-stability for improved
vaccines. In this project, in silico molecular dynamics (MD) simulations, molecular
modelling, free energy calculations, X-ray crystallography, electron microscopy and various
biochemical/biophysical techniques were used to design and help characterise the capsids.
For the most unstable FMDV serotypes (O and SAT2), panels of stabilising mutants were
characterised by MD. Promising candidates were then engineered and shown to confer
increased thermo- and pH-stability. Thus, in silico predictions translate into marked
stabilisation of both infectious and recombinant empty viral capsids. A novel in situ method
was used to determine crystal structures for quality assessment and to verify that no
unanticipated structural changes have occurred as a consequence of the modifications made.
The structures of the wildtype and two of the stabilised mutants were solved and the antigenic
surfaces shown to be unchanged.
Animal trials showed stabilised particles can generate a similar or improved neutralising
antibody response compared to the traditional vaccines and may therefore lead to a new
generation of stable and safe vaccines.
Declaration
ii
DECLARATION OF W Less